Recurrent UTI in Postmenopausal Women with Atrophic Vaginitis: Next Step After Vaginal Estrogen
This protocol addresses the management of recurrent cystitis in postmenopausal women with atrophic vaginitis who have already undergone vaginal estrogen therapy without achieving adequate reduction in urinary tract infection frequency.
Clinical scenario
Postmenopausal women are especially prone to recurrent UTIs due to the increased incidence of atrophic vaginitis and changes in the vaginal microbiome precipitated by lack of estrogenization of the vaginal and lower urinary tracts. This specific combination — postmenopause, atrophic vaginitis, and recurring cystitis — defines a population that requires a structured, stepwise approach.
When the previous treatment has not worked
The first-line step in this pathway is vaginal estrogen (as vaginal rings, creams, or tablets), targeting decreased UTI frequency, lower vaginal pH, reduced vaginal colonisation with Enterobacterales, and recolonisation with Lactobacillus. When these goals are not achieved — in particular when UTI frequency does not improve sufficiently — escalation to the next protocol line is indicated.
Next-line approach
For patients who are unable to derive benefit from vaginal estrogen, antibiotic prophylaxis is the next intervention. The complete selection criteria, strategy, and agent details are outlined in the full protocol.
Goal: decreased frequency of recurrent urinary tract infections
References
DOI: 10.1053/j.ajkd.2023.08.009
- Postmenopausal women are especially prone to recurrent UTIs due to the increased incidence of atrophic vaginitis and changes in the vaginal microbiome precipitated by lack of estrogenization of the tissues in the vaginal and lower urinary tracts.
- For those who are unable to derive benefit from these interventions, antibiotic prophylaxis is often tried.
- Postcoital antibiotics can be effective in decreasing the incidence of UTI and the most well-studied agent is trimethoprim/sulfamethoxazole.
- Continuous prophylaxis has been shown to be effective in clinical trials, but the efficacy is lost once prophylaxis is stopped.